Rakovina Therapeutics closes successful fundraising round to support AI-driven cancer therapy research

From GlobeNewswire: 2024-07-26 21:25:55

Rakovina Therapeutics Inc., a biopharmaceutical company, closed an over-subscribed non-brokered private placement, raising $2 million. The fundraising will support the company’s AI-driven research on DNA-damage response targets to develop new cancer therapies. Defects in DNA-damage responses contribute to 75% of cancers, and Rakovina aims to develop next-generation drugs for clinical trials. The company has issued 19,950,000 units at $0.10 per unit and plans to use the funds for drug candidate research. The private placement is subject to TSX-V acceptance and securities resale restrictions for four months. For more information, visit Rakovina Therapeutics Inc.’s website.



Read more at GlobeNewswire: Rakovina Therapeutics Closes Previously Announced